Country: Australia
Bahasa: Inggeris
Sumber: Department of Health (Therapeutic Goods Administration)
oxaliplatin, Quantity: 50 mg
Alphapharm Pty Ltd
Oxaliplatin
Injection, concentrated
Excipient Ingredients: water for injections
Intravenous
Pack of 1 x vial
(S4) Prescription Only Medicine
Oxaliplatin is indicated for adjuvant treatment of stage III (Duke's C) colon cancer, in combination with a fluoropyrimidine agent,Oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,Oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,Oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer
Visual Identification: Clear, colourless solution, practically free from visible particles; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
2012-03-27